GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » Beneish M-Score

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Beneish M-Score : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for AMAG Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of AMAG Pharmaceuticals was 0.00. The lowest was 0.00. And the median was 0.00.


AMAG Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for AMAG Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals Beneish M-Score Chart

AMAG Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.73 -2.83 -2.20 -3.06 -2.49

AMAG Pharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -2.49 -2.60 -2.98 -2.85

Competitive Comparison of AMAG Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, AMAG Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AMAG Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AMAG Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AMAG Pharmaceuticals's Beneish M-Score falls into.



AMAG Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AMAG Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9274+0.528 * 1.0596+0.404 * 0.9206+0.892 * 0.9396+0.115 * 1.0916
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7379+4.679 * -0.045403-0.327 * 1.2875
=-2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep20) TTM:Last Year (Sep19) TTM:
Total Receivables was $67.6 Mil.
Revenue was 93.106 + 52.755 + 68.661 + 89.484 = $304.0 Mil.
Gross Profit was 79.766 + 34.575 + 44.302 + 46.162 = $204.8 Mil.
Total Current Assets was $283.4 Mil.
Total Assets was $734.4 Mil.
Property, Plant and Equipment(Net PPE) was $23.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $35.7 Mil.
Selling, General, & Admin. Expense(SGA) was $197.0 Mil.
Total Current Liabilities was $162.0 Mil.
Long-Term Debt & Capital Lease Obligation was $308.1 Mil.
Net Income was 9.702 + -13.244 + -24.491 + -200.152 = $-228.2 Mil.
Non Operating Income was -20.794 + 6.225 + 1.311 + -154.857 = $-168.1 Mil.
Cash Flow from Operations was 36.679 + 3.167 + -46.609 + -19.965 = $-26.7 Mil.
Total Receivables was $77.6 Mil.
Revenue was 83.808 + 77.767 + 75.804 + 86.167 = $323.5 Mil.
Gross Profit was 62.703 + 53.477 + 57.327 + 57.451 = $231.0 Mil.
Total Current Assets was $340.8 Mil.
Total Assets was $966.6 Mil.
Property, Plant and Equipment(Net PPE) was $14.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $28.1 Mil.
Selling, General, & Admin. Expense(SGA) was $284.2 Mil.
Total Current Liabilities was $204.1 Mil.
Long-Term Debt & Capital Lease Obligation was $276.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(67.608 / 304.006) / (77.588 / 323.546)
=0.22239 / 0.239805
=0.9274

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(230.958 / 323.546) / (204.805 / 304.006)
=0.713834 / 0.673687
=1.0596

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (283.374 + 23.478) / 734.356) / (1 - (340.839 + 14.554) / 966.608)
=0.582148 / 0.63233
=0.9206

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=304.006 / 323.546
=0.9396

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(28.092 / (28.092 + 14.554)) / (35.729 / (35.729 + 23.478))
=0.658725 / 0.603459
=1.0916

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(197.048 / 304.006) / (284.203 / 323.546)
=0.648171 / 0.878401
=0.7379

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((308.06 + 161.977) / 734.356) / ((276.468 + 204.074) / 966.608)
=0.640067 / 0.497143
=1.2875

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-228.185 - -168.115 - -26.728) / 734.356
=-0.045403

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AMAG Pharmaceuticals has a M-score of -2.85 suggests that the company is unlikely to be a manipulator.


AMAG Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.
Executives
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano officer: Chief Operating Officer C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos officer: Interim CFO C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson director, 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat director
Davey Scoon director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers director, officer: President & CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick officer: Chief Human Resources Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Headlines

From GuruFocus